Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 22, 2024

BUY
$101.21 - $166.61 $1.13 Million - $1.86 Million
11,190 New
11,190 $1.36 Million
Q3 2023

Oct 30, 2023

SELL
$96.41 - $126.61 $883,115 - $1.16 Million
-9,160 Reduced 92.71%
720 $72,000
Q2 2023

Jul 17, 2023

SELL
$118.5 - $160.53 $1.56 Million - $2.11 Million
-13,163 Reduced 57.12%
9,880 $1.21 Million
Q1 2023

May 02, 2023

BUY
$135.66 - $197.02 $1.39 Million - $2.02 Million
10,262 Added 80.29%
23,043 $3.4 Million
Q4 2022

Jan 26, 2023

BUY
$118.38 - $210.04 $1.51 Million - $2.68 Million
12,781 New
12,781 $2.28 Million
Q2 2022

Jul 19, 2022

SELL
$117.13 - $176.59 $16,398 - $24,722
-140 Closed
0 $0
Q1 2022

May 03, 2022

SELL
$126.46 - $235.05 $1.3 Million - $2.41 Million
-10,264 Reduced 98.65%
140 $24,000
Q4 2021

Feb 07, 2022

BUY
$225.82 - $368.51 $1.92 Million - $3.14 Million
8,518 Added 451.64%
10,404 $2.61 Million
Q3 2021

Oct 25, 2021

SELL
$221.9 - $484.47 $290,245 - $633,686
-1,308 Reduced 40.95%
1,886 $726,000
Q2 2021

Jul 26, 2021

SELL
$129.91 - $234.98 $311,004 - $562,542
-2,394 Reduced 42.84%
3,194 $2.45 Million
Q1 2021

Apr 27, 2021

BUY
$109.18 - $185.98 $172,395 - $293,662
1,579 Added 39.39%
5,588 $2.45 Million
Q4 2020

Jan 26, 2021

SELL
$65.74 - $169.86 $46,806 - $120,940
-712 Reduced 15.08%
4,009 $1.35 Million
Q3 2020

Oct 20, 2020

SELL
$54.34 - $94.85 $15,160 - $26,463
-279 Reduced 5.58%
4,721 $334,000
Q2 2020

Jul 14, 2020

BUY
$29.67 - $80.0 $115,713 - $312,000
3,900 Added 354.55%
5,000 $321,000
Q1 2020

Apr 28, 2020

BUY
$17.78 - $31.58 $19,558 - $34,738
1,100 New
1,100 $33,000
Q4 2019

Jan 23, 2020

SELL
$13.93 - $21.28 $5,376 - $8,214
-386 Closed
0 $0
Q3 2019

Nov 06, 2019

BUY
$12.26 - $18.07 $4,732 - $6,975
386 New
386 $6,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Harel Insurance Investments & Financial Services Ltd. Portfolio

Follow Harel Insurance Investments & Financial Services Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harel Insurance Investments & Financial Services Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Harel Insurance Investments & Financial Services Ltd. with notifications on news.